400 related articles for article (PubMed ID: 15584490)
21. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
[TBL] [Abstract][Full Text] [Related]
22. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
[TBL] [Abstract][Full Text] [Related]
23. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.
Delgado M; Reduta A; Sharma V; Ganea D
J Leukoc Biol; 2004 Jun; 75(6):1122-30. PubMed ID: 15020654
[TBL] [Abstract][Full Text] [Related]
24. MOG extracellular domain (p1-125) triggers elevated frequency of CXCR3+ CD4+ Th1 cells in the CNS of mice and induces greater incidence of severe EAE.
Mony JT; Khorooshi R; Owens T
Mult Scler; 2014 Sep; 20(10):1312-21. PubMed ID: 24552747
[TBL] [Abstract][Full Text] [Related]
25. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression.
Delgado M; Sun W; Leceta J; Ganea D
J Immunol; 1999 Oct; 163(8):4213-23. PubMed ID: 10510358
[TBL] [Abstract][Full Text] [Related]
26. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
Zheng H; Zhang H; Liu F; Qi Y; Jiang H
Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
[TBL] [Abstract][Full Text] [Related]
27. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
[TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis.
Natarajan C; Muthian G; Barak Y; Evans RM; Bright JJ
J Immunol; 2003 Dec; 171(11):5743-50. PubMed ID: 14634082
[TBL] [Abstract][Full Text] [Related]
29. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis.
Nath N; Giri S; Prasad R; Salem ML; Singh AK; Singh I
J Immunol; 2005 Jul; 175(1):566-74. PubMed ID: 15972693
[TBL] [Abstract][Full Text] [Related]
30. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
31. The central nervous system environment controls effector CD4+ T cell cytokine profile in experimental allergic encephalomyelitis.
Krakowski ML; Owens T
Eur J Immunol; 1997 Nov; 27(11):2840-7. PubMed ID: 9394808
[TBL] [Abstract][Full Text] [Related]
32. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis.
Juedes AE; Ruddle NH
J Immunol; 2001 Apr; 166(8):5168-75. PubMed ID: 11290800
[TBL] [Abstract][Full Text] [Related]
33. Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis.
Tseveleki V; Tselios T; Kanistras I; Koutsoni O; Karamita M; Vamvakas SS; Apostolopoulos V; Dotsika E; Matsoukas J; Lassmann H; Probert L
Exp Neurol; 2015 May; 267():254-67. PubMed ID: 25447934
[TBL] [Abstract][Full Text] [Related]
34. Silencing c-Rel in macrophages dampens Th1 and Th17 immune responses and alleviates experimental autoimmune encephalomyelitis in mice.
Zhang H; Bi J; Yi H; Fan T; Ruan Q; Cai L; Chen YH; Wan X
Immunol Cell Biol; 2017 Aug; 95(7):593-600. PubMed ID: 28202908
[TBL] [Abstract][Full Text] [Related]
35. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway.
Li G; Yamasaki R; Fang M; Masaki K; Ochi H; Matsushita T; Kira JI
Sci Rep; 2018 Jan; 8(1):1933. PubMed ID: 29386552
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
37. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
38. Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation.
Becquet L; Abad C; Leclercq M; Miel C; Jean L; Riou G; Couvineau A; Boyer O; Tan YV
J Neuroinflammation; 2019 Mar; 16(1):64. PubMed ID: 30894198
[TBL] [Abstract][Full Text] [Related]
39. [Neuroprotective effects of novel derivatives of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide in two brain ischemic models on mice].
Takeda N; Murozono M; Watanabe S; Isshiki A; Watanabe Y
Masui; 2005 Mar; 54(3):240-8. PubMed ID: 15794099
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Yang EJ; Stokes JV; Kummari E; Eells J; Kaplan BL
Toxicol Sci; 2016 May; 151(1):35-43. PubMed ID: 26822306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
